Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522530 | 0.85 | CYP19A1 (0.41) | OPRM1OPRK1LMNACYP19A1 | |
| SCHEMBL10046471 | 0.83 | OPRM1 (0.44) | OPRM1OPRL1OPRD1OPRK1LMNA | |
| SCHEMBL10046470 | 0.83 | SLC6A3 (0.47) | OPRM1OPRL1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL10046459 | 0.82 | PTAFR (0.42) | OPRM1OPRD1OPRK1CYP19A1 | |
| SCHEMBL522532 | 0.81 | SLC6A3 (0.44) | OPRM1OPRL1OPRD1OPRK1LMNA | |
| SCHEMBL10046469 | 0.81 | CYP19A1 (0.47) | OPRM1OPRL1OPRD1OPRK1LMNA | |
| SCHEMBL521510 | 0.78 | PTAFR (0.46) | OPRM1 | |
| SCHEMBL522353 | 0.78 | PTAFR (0.47) | OPRM1OPRL1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL10046467 | 0.77 | ALDH1A1 (0.42) | OPRM1OPRL1OPRD1OPRK1CACNA2D1 | |
| SCHEMBL521671 | 0.75 | PTAFR (0.45) | OPRM1OPRL1OPRD1OPRK1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | CLIC1, NAT1, NMRAL1 | OPRM1 677/4885OPRL1 607/4885OPRD1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.